| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
4,035,000 |
| Market
Cap: |
157.37(K) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.034 - $0.047 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Quotient is a commercial-stage diagnostics company. Co. focuses on blood grouping and donor disease screening, which is referred to as transfusion diagnostics. Co. is developing MosaiQ for immunohematology (blood grouping), serological disease screening, and molecular disease screening. Co.'s reagent products, which are branded as Alba by Quotient, are used primarily to identify blood group antigens and antibodies in donor and patient blood and to perform testing for third-party blood grouping instrument platforms. Co. also undertakes product development projects for its original equipment manufacturer customers.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
10,551,472 |
| Total Buy Value |
$0 |
$0 |
$0 |
$3,053,515 |
| Total People Bought |
0 |
0 |
0 |
6 |
| Total Buy Transactions |
0 |
0 |
0 |
9 |
| Total Shares Sold |
0 |
0 |
0 |
8,286,484 |
| Total Sell Value |
$0 |
$0 |
$0 |
$690,841 |
| Total People Sold |
0 |
0 |
0 |
4 |
| Total Sell Transactions |
0 |
0 |
0 |
5 |
| End Date |
2024-03-07 |
2023-12-05 |
2023-06-06 |
2022-06-06 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Cowan D J Paul E |
See Remarks |
• • – |
2017-08-17 |
4 |
AS |
$4.03 |
$43,153 |
I/I |
(10,708) |
3,404,049 |
|
- |
|
| Cowan D J Paul E |
See Remarks |
• • – |
2017-08-16 |
4 |
AS |
$4.03 |
$66,370 |
I/I |
(16,469) |
3,414,757 |
|
- |
|
| Cowan D J Paul E |
See Remarks |
• • – |
2017-08-15 |
4 |
AS |
$4.09 |
$111,587 |
I/I |
(27,283) |
3,431,226 |
|
- |
|
| Cowan D J Paul E |
See Remarks |
• • • |
2017-07-20 |
4 |
AS |
$6.11 |
$57,556 |
I/I |
(9,420) |
3,458,509 |
|
- |
|
| Cowan D J Paul E |
See Remarks |
• • • |
2017-07-19 |
4 |
AS |
$6.14 |
$153,304 |
I/I |
(24,968) |
3,467,929 |
|
- |
|
| Cowan D J Paul E |
See Remarks |
• • • |
2017-07-18 |
4 |
AS |
$6.29 |
$129,448 |
I/I |
(20,580) |
3,492,897 |
|
- |
|
| Cowan D J Paul E |
See Remarks |
• • • |
2017-07-17 |
4 |
AS |
$6.57 |
$295,860 |
I/I |
(45,032) |
3,513,477 |
|
- |
|
| Hallsworth Frederick |
Director |
– • – |
2017-03-23 |
4 |
S |
$6.65 |
$173 |
D/D |
(26) |
55,065 |
|
- |
|
| Lindop Christopher J |
Chief Financial Officer |
• – – |
2017-02-09 |
4 |
A |
$6.41 |
$320,500 |
D/D |
50,000 |
50,000 |
|
- |
|
| Mcdonough Brian |
Director |
– • – |
2016-10-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,291 |
23,345 |
|
- |
|
| Bologna Thomas A |
Director |
– • – |
2016-10-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,291 |
138,274 |
|
- |
|
| Von Prondzynski Heino |
Director |
– • – |
2016-10-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,291 |
31,225 |
|
- |
|
| Oconnor Sarah A |
Director |
– • – |
2016-10-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,291 |
11,291 |
|
- |
|
| Von Prondzynski Heino |
Director |
– • – |
2016-09-04 |
4 |
OE |
$0.00 |
$0 |
D/D |
17,434 |
29,934 |
|
- |
|
| Galen Partners V, L.l.c. |
10% Owner |
– – • |
2016-08-03 |
4 |
B |
$5.50 |
$990,000 |
I/I |
180,000 |
6,489,618 |
1.5 |
- |
|
| Wilkerson L John |
Director |
– • • |
2016-08-03 |
4 |
B |
$5.50 |
$990,000 |
I/I |
180,000 |
6,489,618 |
2.25 |
- |
|
| Shroff Zubeen |
Director |
– • • |
2016-08-03 |
4 |
B |
$5.50 |
$990,000 |
I/I |
180,000 |
6,489,618 |
2.25 |
- |
|
| Cowan D J Paul E |
See Remarks |
• • • |
2016-08-03 |
4 |
B |
$5.50 |
$250,003 |
I/I |
45,455 |
3,558,509 |
2.64 |
- |
|
| Quotient Biodiagnostics Group Ltd |
10% Owner |
– – • |
2016-08-03 |
4 |
B |
$5.50 |
$250,003 |
I/I |
45,455 |
3,558,509 |
1.5 |
- |
|
| Stackawitz Jeremy |
President |
• – – |
2016-06-09 |
4 |
S |
$10.00 |
$150,000 |
D/D |
(15,000) |
127,741 |
|
- |
|
| Unger Stephen |
Chief Financial Officer |
• – – |
2016-06-03 |
4 |
S |
$9.99 |
$144,695 |
D/D |
(14,484) |
0 |
|
- |
|
| Unger Stephen |
Chief Financial Officer |
• – – |
2016-06-02 |
4 |
S |
$10.43 |
$73,146 |
D/D |
(7,013) |
14,484 |
|
- |
|
| Unger Stephen |
Chief Financial Officer |
• – – |
2016-06-01 |
4 |
S |
$10.78 |
$16,202 |
D/D |
(1,503) |
21,497 |
|
- |
|
| Hallsworth Frederick |
Director |
– • – |
2016-03-24 |
4 |
S |
$8.59 |
$189 |
D/D |
(22) |
55,091 |
|
- |
|
| Galen Partners V, L.l.c. |
10% Owner |
– – • |
2016-02-10 |
4 |
B |
$9.00 |
$1,999,998 |
I/I |
222,222 |
6,309,618 |
1.5 |
- |
|
351 Records found
|
|
Page 13 of 15 |
|
|
